Samara Capital prone to buy Novartis brands

Several weeks after sealing an offer with Ahmedabad-based Torrent Pharma for that purchase of a couple of its leading women’s healthcare brands, Swiss pharmaceutical major Novartis AG has become in advanced stages of promoting its niche portfolio of anti-infective brands included in its ongoing technique to divest non-core portfolios in India, two sources acquainted with the suggested transaction told ET NOW on the health of anonymity.

“Samara Capital may be the front-runner at this time as well as an official announcement is anticipated shortly. Samara Capital is bullish about this segment and seven-8 brands which are members of the anti-infective portfolio is going to be acquired included in the deal,” stated among the two sources reported above.

“These anti-infective brands is going to be accretive to Samara Capital because they are searching to produce a strong women’s healthcare portfolio making the brands open to general practioners in addition to gynaecologists,” added the 2nd source.

In April 2016, South African drug maker Adcock Ingram Holdings Limited exited its pharmaceutical operations in India by selling its drug marketing and purchase business to Samara Capital for Rs.151 crore. The suggested cope with Novartis AG would complement this earlier transaction, sources added. Boutique investment bank Torreya Partners may be the consultant towards the transaction, they added.

“The organization has completed the purchase of Regestrone and Pregachieve brands for India from global pharma player Novartis AG, Europe. These brands are broadly prescribed by gynaecologists for the treating of abnormal uterine bleeding, Peri and Publish-menopausal signs and symptoms and Infertility,” Torrent Pharma announced within an official statement at the begining of May, 2016?

Samara Capital is definitely an entrepreneurially run India-focused private equity finance firm founded in the year 2006 by Sumit Narang and Gautam Gode.

ET Now’s waiting for email responses from Samara Capital and Novartis around the suggested transaction. An e-mail delivered to the London office of Torreya Partners went unanswered during the time of likely to press.

Leave a Reply

Your email address will not be published. Required fields are marked *